论文部分内容阅读
Thymic carcinoid is a rare neoplasm with unclear risk factors and controversial classifications.Clinical manifestations vary from asymptomatic to many nonspecific symptoms,among which endocrinopathy seems to be associated with poor prognosis.Quantitative and qualitative analysis of ACTH and prognosis could become a topic in the future.Image studies show no specificity both in CT and PET/CT,but are of great value in clinical staging.The diagnosis of thymic carcinoid mainly depends on pathology and immunohistochemistry plays a role in differential diagnosis.Ki67 has been found to be a powerful tool for grading neuroendocrine tumors and further studies should be made.Radical resection is the first choice in treatment,and target therapy becomes possible with the development in molecular pathology.However,since the rarity of thymic carcinoid, there is no practical clinical staging or standard guideline to instruct clinical practice.Thus, support of International Thymic Malignancy Interest Group (ITMIG) seems to be of great significance in case collection and resource sharing.In this article,we are going to put forward a strategyavailable in clinical application for diagnoisis and treatment of thymic carcinoid by using a new clinical staging system.